APT(SH:688617) Sou Hu Cai Jing·2025-08-21 22:59Core Insights - Huatai Medical (688617.SH) reported a total revenue of 1.214 billion yuan for the first half of 2025, with a net profit attributable to shareholders of 425 million yuan [1][1]. - The company achieved a net cash inflow from operating activities of 445 million yuan [1][1]. Financial Performance - The latest debt-to-asset ratio stands at 12.20% [1][1]. - The gross profit margin is reported at 73.51% [1][1]. - Return on equity (ROE) is at 15.21%, reflecting a decrease of 0.85 percentage points compared to the same period last year [1][1]. - The diluted earnings per share (EPS) is 3.02 yuan [1][1]. - Total asset turnover ratio is 0.39 times, while inventory turnover ratio is 0.77 times, showing a decline of 0.02 times or 3.10% year-on-year [1][1]. Shareholder Structure - The number of shareholders is 4,507, with the top ten shareholders holding a total of 82.4439 million shares, accounting for 58.46% of the total share capital [1][1]. - The largest shareholder is Shenzhen Mindray Technology Holding Co., Ltd., holding 21.0% of shares [1][1]. - Other significant shareholders include Cheng Zhenghui (18.71%), Zhuhai Tongyi Investment Partnership (3.48%), and others [1][1].